I. Judson

发表

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

O. S. Nielsen, S. Rodenhuis, M. van Glabbeke, 1999, European journal of cancer.

Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata

P. Woll, P. Gaunt, C. Gaskell, 2023, British Journal of Cancer.

CLINICAL Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up † the ESMO Guidelines Committee and EURACAN*

E. Álava, A. Cesne, H. Joensuu, 2020 .

Investigating the heterogeneity of alkylating agents’ efficacy and toxicity between sexes: A systematic review and meta‐analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)

J.R. Anderson, U. Dirksen, J. Pignon, 2017, Pediatric blood & cancer.

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

I Judson, J Verweij, J. Blay, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of

J. Blay, S. Rodenhuis, M. van Glabbeke, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S. Litière, A. Cesne, H. Joensuu, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer.

T. Powles, R. Coombes, I. Judson, 1990, European journal of cancer.

Sensitivity of well-differentiated/dedifferentiated liposarcoma (WD/DD) and myxoid round cell/liposarcoma (MRCL) to high-dose ifosfamide: Combined analysis from two European referral institutions.

P. Casali, I. Judson, S. Pilotti, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.

O. S. Nielsen, M. van Glabbeke, J. Verweij, 2002, European journal of cancer.

Advances in the treatment of gastrointestinal stromal tumours.

I Judson, G. Demetri, I. Judson, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series

R. C. Smith, I. Judson, A. Miah, 2017, Clinical Sarcoma Research.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S. Sleijfer, E. Álava, E. Wardelmann, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072).

J. Blay, A. Cesne, A. D. Dei Tos, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted therapies in soft tissue sarcomas.

I. Judson, I. Judson, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.

J. Blay, J. Radford, J. Verweij, 2001, European journal of cancer.

STI571: a magic bullet?

J. Verweij, A. V. van Oosterom, I. Judson, 2001, European journal of cancer.

RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma.

M. van Glabbeke, P. Therasse, J. Verweij, 2005, European journal of cancer.

Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial?

J. Blay, J. Verweij, M. Glabbeke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.